David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman,...
Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis
Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...
Abby Statler: Are Clinical Trials Exclusion Criteria for AML Too Strict?
Abby Statler, PhD, MPH, discusses findings from an analysis of common clinical trial exclusion criteria and outcomes in clinical trials, which suggest that eligibility...
James Foran: Does Decitabine Maintenance Improve Survival in Older Patients With AML?
James M. Foran, MD, shares “compelling, but not definitive” results that appear to support the use of maintenance therapy with decitabine in older adults...
Saad Usmani: Adding Daratumumab to Carfilzomib + Dexamethasone Extends PFS
Saad Usmani, MD, MBBS, shares findings from the CANDOR trial, in which the three-drug combination reduced the risk of disease progression or death by...
Stephen Schuster: Mosunetuzumab Leads to Durable Complete Remissions in Non-Hodgkin Lymphoma
Patients with both indolent and aggressive non-Hodgkin lymphomas responded to treatment with the monoclonal antibody, even those whose disease had not responded to CAR...
Patrick Brown: Is Blinatumomab a New Standard of Care for Young Patients With B-Cell...
Patrick A. Brown, MD, discusses the results seen with blinatumomab as consolidation therapy in young patients with higher-risk, relapsed B-cell acute lymphocytic leukemia, where...
Megan Brown: Improving VWD Testing in Girls With Heavy Menstrual Bleeding
Megan C. Brown, MD, describes results from an emergency department–based initiative to improve the diagnostic accuracy of testing for von Willebrand disease in adolescents...
Rajat Bannerji: REGN1979 Active Across Non-Hodgkin Lymphoma Subtypes
The bispecific antibody REGN1979 demonstrated efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, with no observed dose-limiting toxicities. Rajat Bannerji, MD, PhD,...
Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma
Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
